Talk with your clinician about whether your family history, smoking history, previous findings, or other risk factors mean you need a different screening plan.
Early detection still matters.
🤦♂️ Cancer screening recommendations should be current, transparent, and based on evidence.
These guidelines don't just guide doctors—they also influence which preventive services insurers cover without patients paying out of pocket.
https://t.co/frQP8bVoaC
Patients shouldn't assume a delayed policy process changes what they should do today.
In most cases, it doesn't.
If you're due for recommended screening based on your age and risk, don't put it off because of headlines.
For many people with MSS colorectal cancer, immunotherapy alone has not been enough.
That can be frustrating, especially after multiple prior treatments.
#ColorectalCancer#MSS#ClinicalTrials
This study is for MSS/pMMR disease in the third-line or later setting, and patients are assigned to different treatment groups.
If this sounds close to your situation, ask whether MSS/pMMR status and treatment history point to any trial options.
Trying to understand which breast cancer trials may fit your diagnosis, stage, biomarkers, and treatment history?
Get a free personalized Sagely trial report: https://t.co/geR6sxjOoE
For some people with ER+, HER2− breast cancer after surgery, the cancer may look higher-risk by stage but lower-risk by genomic testing.
A Phase 3 study is asking whether that biology can help guide who may need chemotherapy.
#BreastCancer
Why it matters: this study asks whether some patients can avoid chemotherapy when tumor biology suggests lower genomic risk, even if stage suggests higher risk.
Study Link: https://t.co/HoKTh7zuTk
July is Sarcoma and Bone Cancer Awareness Month.
Most bone pain is not cancer. But pain that persists, worsens at night, causes swelling, creates a lump, or does not fit a clear injury deserves attention.
#BoneCancerAwarenessMonth#SarcomaAwarenessMonth#Sarcoma
What he shared publicly still matters: patients deserve to know when specialized treatments or clinical trials may offer another option after standard treatment stops working. CAR-T will not fit every patient, but people should have the chance to ask.
Our condolences to Sam Neill’s family and everyone who loved him.
Sam spoke openly about living with a rare blood cancer, treatment stopping working, and entering a CAR-T clinical trial. Earlier this year, he shared that his scans showed no cancer.
https://t.co/mN5AP39A4l
His family has said his death was sudden and unexpected, and that he remained cancer-free. That distinction matters. This should not be described as a death from cancer.
Liv is also participating in research studying whether metformin can reduce cancer risk in people with Li-Fraumeni syndrome. We don't know the answer yet—but this is exactly why clinical research matters.
Liv and Sam's story is inspiring, but an important part is what it means to live with Li-Fraumeni syndrome, an inherited condition that can mean lifelong cancer screening, repeated scans, and difficult preventive decisions.
https://t.co/1lEfwrtqWz